These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37996193)

  • 21. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents.
    Caprio M; Vitale C; Rosano GMC
    Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):83-85. PubMed ID: 32298414
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Riccardi G;
    Lancet; 2014 Sep; 384(9948):1096. PubMed ID: 25241718
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes.
    Boussageon R
    Lancet; 2014 Sep; 384(9948):1096-7. PubMed ID: 25241717
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes.
    Yudkin JS; Vijan S; Sussman JB; Lehman R; Goldacre BM
    Lancet; 2014 Sep; 384(9948):1095. PubMed ID: 25241716
    [No Abstract]   [Full Text] [Related]  

  • 26. Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent.
    Sternlicht H; Bakris GL
    Nat Rev Nephrol; 2016 Mar; 12(3):128-9. PubMed ID: 26714579
    [No Abstract]   [Full Text] [Related]  

  • 27. Meta-Analysis on the Efficacy of Novel Glucose-Lowering Agents in Older Patients With Type 2 Diabetes Mellitus.
    Ahmed A; Imran L; Naeem U; Jawed A; Jawed A; Khan Z; Arshad AR; Arshad MS
    Am J Cardiol; 2023 Jan; 187():127-130. PubMed ID: 36459735
    [No Abstract]   [Full Text] [Related]  

  • 28. Intensive glucose lowering and cognition in type 2 diabetes.
    Biessels GJ
    Lancet Neurol; 2011 Nov; 10(11):949-50. PubMed ID: 21958948
    [No Abstract]   [Full Text] [Related]  

  • 29. Intensified glucose lowering in type 2 diabetes: don't throw the baby out with the bathwater.
    DeVries JH
    Diabetologia; 2011 Mar; 54(3):705-6; author reply 707-8. PubMed ID: 21127831
    [No Abstract]   [Full Text] [Related]  

  • 30. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
    Hoogwerf BJ
    Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucose-lowering therapy after myocardial infarction: more questions than answers.
    Radke PW; Schunkert H
    Eur Heart J; 2008 Jan; 29(2):141-3. PubMed ID: 18199566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
    Martens P; Janssens J; Ramaekers J; Dupont M; Mullens W
    Acta Cardiol; 2020 Jun; 75(3):211-217. PubMed ID: 30736724
    [No Abstract]   [Full Text] [Related]  

  • 33. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.
    Bergenstal RM; Bailey CJ; Kendall DM
    Am J Med; 2010 Apr; 123(4):374.e 9 -18. PubMed ID: 20362759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
    Holman RR; Sourij H; Califf RM
    Lancet; 2014 Sep; 384(9948):1097-8. PubMed ID: 25241719
    [No Abstract]   [Full Text] [Related]  

  • 35. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review.
    Golden SH; Sapir T
    J Manag Care Pharm; 2012 Aug; 18(6 Suppl):S1-17. PubMed ID: 22984955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
    Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
    Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
    Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucose-lowering effects of sulfasalazine in type 2 diabetes.
    Haas RM; Li P; Chu JW
    Diabetes Care; 2005 Sep; 28(9):2238-9. PubMed ID: 16123497
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy.
    Bakris G
    J Fam Pract; 2019 Oct; 68(8):S1-S6. PubMed ID: 31697796
    [No Abstract]   [Full Text] [Related]  

  • 40. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
    Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
    Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.